Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network
- PMID: 31580448
- PMCID: PMC7244786
- DOI: 10.1093/rheumatology/kez461
Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network
Abstract
Objectives: To examine associations between function, quality of life and structural outcomes in patients achieving remission vs low disease activity in early RA.
Methods: Demographic, clinical and radiographic variables were collected at baseline and then annually from the Early Rheumatoid Arthritis Study (ERAS) and Early Rheumatoid Arthritis Network (ERAN) inception cohorts in routine care from 1986 to 2012. Disease activity was categorized: mean DAS28 score between years 1 and 5: remission [mean remission DAS (mRDAS) <2.6] or low [mean low DAS (mLDAS) 2.6-3.2]; sustained low/remission DAS28 (sLDAS/sRDAS) at years 1 and 2; and sustained Boolean remission (sBR) at years 1 and 2. Changes in HAQ and Short Form 36 Health Survey Questionnaire [SF-36; physical (PCS) and mental (MCS) component score]) and total Sharp van der Heijde (SvdH) scores for each disease activity category were modelled using multi-level models. Covariates included year of onset, age, gender and DMARD use at first visit.
Results: Of 2701 patients, 562 (21%) were categorized mRDAS, 330 (12%) mLDAS, 279 (10%) sRDAS, 203 (7.5%) sLDAS and 93 (3%) sBR. Patients categorized as mRDAS had increasingly divergent improved HAQ, SF-36 PCS, MCS and total SvdH scores compared with mLDAS (P-values 0.001 to <0.0001, all time points). Patients categorized as sRDAS had better HAQ, SF-36 PCS and MCS scores (P-values 0.05 to <0.0001, all time points) and SvdH scores (P = 0.05, years 3-5) over sLDAS. sBR was associated with better HAQ, and SF-36 PCS and MCS scores over sLDAS (P-values 0.002 to <0.0001, all time points).
Conclusion: These findings from routine care support ACR/EULAR guidelines that remission is a preferable goal over low disease activity in early RA.
Keywords: damage; function; life quality; low disease activity; remission; rheumatoid arthritis.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Figures



Similar articles
-
Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.Arthritis Care Res (Hoboken). 2013 Aug;65(8):1219-26. doi: 10.1002/acr.21984. Arthritis Care Res (Hoboken). 2013. PMID: 23436821 Clinical Trial.
-
Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target.Joint Bone Spine. 2019 Oct;86(5):594-599. doi: 10.1016/j.jbspin.2019.03.008. Epub 2019 Mar 27. Joint Bone Spine. 2019. PMID: 30928534
-
Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.Intern Med. 2017 Sep 1;56(17):2271-2275. doi: 10.2169/internalmedicine.8723-16. Epub 2017 Aug 10. Intern Med. 2017. PMID: 28794381 Free PMC article.
-
Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.Rheumatology (Oxford). 2014 Jun;53(6):1075-86. doi: 10.1093/rheumatology/ket449. Rheumatology (Oxford). 2014. PMID: 24501240 Review.
-
Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis.Curr Rheumatol Rep. 2012 Oct;14(5):472-80. doi: 10.1007/s11926-012-0275-1. Curr Rheumatol Rep. 2012. PMID: 22773387 Free PMC article. Review.
Cited by
-
Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?Lancet Rheumatol. 2020 Aug;2(8):e454-e456. doi: 10.1016/S2665-9913(20)30175-2. Epub 2020 Jun 8. Lancet Rheumatol. 2020. PMID: 32835250 Free PMC article. No abstract available.
-
Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity.Arthritis Res Ther. 2023 Oct 20;25(1):207. doi: 10.1186/s13075-023-03176-7. Arthritis Res Ther. 2023. PMID: 37864239 Free PMC article.
-
Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems.Front Med (Lausanne). 2022 Oct 24;9:1049875. doi: 10.3389/fmed.2022.1049875. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36353219 Free PMC article. Review.
-
Comprehensive evaluation of the influence of sex differences on composite disease activity indices for rheumatoid arthritis: results from a nationwide observational cohort study.BMC Rheumatol. 2023 Mar 21;7(1):4. doi: 10.1186/s41927-023-00328-9. BMC Rheumatol. 2023. PMID: 36945056 Free PMC article.
-
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study.Cost Eff Resour Alloc. 2024 Feb 14;22(1):14. doi: 10.1186/s12962-024-00522-7. Cost Eff Resour Alloc. 2024. PMID: 38355532 Free PMC article.
References
-
- Smolen JS, Landewé R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals Rheum Dis 2017;76:960–77. - PubMed
-
- Singh JA, Saag KG, Bridges SL. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1–25. - PubMed
-
- Rheumatoid arthritis in adults: management. NICE Clinical Guideline 100, published July 2018. https://ww.nice.org.uk/guidance/ng100 (31 May 2019, date last accessed).
-
- Bukhari M. Is remission achievable in most patients with rheumatoid arthritis? Results suggest not. Rheumatology (Oxford) 2019;58:187–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical